Ublituximab, marketed under the brand name Briumvi, is a CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Ublituximab was approved by the FDA on December 28, 2022.

Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.

Xenoview received FDA approval on December 23, 2022. It plays a crucial role in providing clearer images of certain areas of the body, particularly the lungs, without the need for radiation exposure.

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis.

Adstiladrin received FDA approval on December 16, 2022. It represents a significant advancement in cancer therapy, particularly for patients who have not responded to standard treatments.

Jul 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Adagrasib, marketed under the brand name Krazati, is an oral medication used to treat adults with non-small cell lung cancer (NSCLC).

OSE Immunotherapeutics Reports Promising Phase 2 Trial Outcomes for Lusvertikimab in Ulcerative Colitis Treatment.

Olutasidenib received FDA approval on December 1, 2022. This drug belongs to the class of miscellaneous antineoplastics.

IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.

Rebyota, a fecal microbiota product, is used to prevent the recurrence of Clostridioides difficile infection (CDI).

Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.